Pfizer ticks off Lyme vaccine milestone, linking booster shot to pediatric antibody response

Pfizer and Valneva have ticked off another milestone in their Lyme disease vaccine program, showing that booster doses safely trigger immune responses in adolescents and younger children in a phase 2 clinical trial.